Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : TLT-101
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Financing
TikkunLev Therapeutics Develops Precision Therapies for Heart Failure Biology
Details : The proceeds from the seed financing will support ongoing clinical development of TLT-101 for multiple serious forms of heart failure, with an initial focus on non-ischemic dilated cardiomyopathy.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
October 29, 2024
Lead Product(s) : TLT-101
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Financing
LOOKING FOR A SUPPLIER?